190 related articles for article (PubMed ID: 22209730)
1. A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides.
Rikimaru K; Wakabayashi T; Abe H; Imoto H; Maekawa T; Ujikawa O; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
Bioorg Med Chem; 2012 Jan; 20(2):714-33. PubMed ID: 22209730
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists.
Rikimaru K; Wakabayashi T; Abe H; Tawaraishi T; Imoto H; Yonemori J; Hirose H; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
Bioorg Med Chem; 2012 May; 20(10):3332-58. PubMed ID: 22503460
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators.
Kumar R; Mittal A; Ramachandran U
Bioorg Med Chem Lett; 2007 Aug; 17(16):4613-8. PubMed ID: 17574414
[TBL] [Abstract][Full Text] [Related]
5. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
Shibata Y; Kagechika K; Yamaguchi M; Kubo H; Usui H
Bioorg Med Chem Lett; 2012 Dec; 22(23):7075-9. PubMed ID: 23084275
[TBL] [Abstract][Full Text] [Related]
7. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
[TBL] [Abstract][Full Text] [Related]
8. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
Peng YH; Coumar MS; Leou JS; Wu JS; Shiao HY; Lin CH; Lin WH; Lien TW; Chen X; Hsu JT; Chao YS; Huang CF; Lyu PC; Hsieh HP; Wu SY
ChemMedChem; 2010 Oct; 5(10):1707-16. PubMed ID: 20734309
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412
[TBL] [Abstract][Full Text] [Related]
12. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
[TBL] [Abstract][Full Text] [Related]
13. INT-131, a PPARgamma agonist for the treatment of type 2 diabetes.
Kintscher U; Goebel M
Curr Opin Investig Drugs; 2009 Apr; 10(4):381-7. PubMed ID: 19337960
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist.
Bajare S; Anthony J; Nair A; Marita R; Damre A; Patel D; Rao C; Sivaramakrishnan H; Deka N
Eur J Med Chem; 2012 Dec; 58():355-60. PubMed ID: 23142675
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
Pingali H; Jain M; Shah S; Makadia P; Zaware P; Goel A; Patel M; Giri S; Patel H; Patel P
Bioorg Med Chem; 2008 Aug; 16(15):7117-27. PubMed ID: 18625559
[TBL] [Abstract][Full Text] [Related]
16. Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity.
Taygerly JP; McGee LR; Rubenstein SM; Houze JB; Cushing TD; Li Y; Motani A; Chen JL; Frankmoelle W; Ye G; Learned MR; Jaen J; Miao S; Timmermans PB; Thoolen M; Kearney P; Flygare J; Beckmann H; Weiszmann J; Lindstrom M; Walker N; Liu J; Biermann D; Wang Z; Hagiwara A; Iida T; Aramaki H; Kitao Y; Shinkai H; Furukawa N; Nishiu J; Nakamura M
Bioorg Med Chem; 2013 Feb; 21(4):979-92. PubMed ID: 23294830
[TBL] [Abstract][Full Text] [Related]
17. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Henry JR; Li Y; Warshawsky AM; Brozinick JT; Hawkins ED; Misener EA; Briere DA; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Ajamie RT; Wilken B; Devanarayan V
Bioorg Med Chem Lett; 2006 Dec; 16(24):6293-7. PubMed ID: 17005393
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and molecular docking of thiazolidinedione based benzene sulphonamide derivatives containing pyrazole core as potential anti-diabetic agents.
Naim MJ; Alam O; Alam MJ; Hassan MQ; Siddiqui N; Naidu VGM; Alam MI
Bioorg Chem; 2018 Feb; 76():98-112. PubMed ID: 29169079
[TBL] [Abstract][Full Text] [Related]
19. Truxillic acid derivatives act as peroxisome proliferator-activated receptor gamma activators.
Steri R; Rupp M; Proschak E; Schroeter T; Zettl H; Hansen K; Schwarz O; Müller-Kuhrt L; Müller KR; Schneider G; Schubert-Zsilavecz M
Bioorg Med Chem Lett; 2010 May; 20(9):2920-3. PubMed ID: 20347594
[TBL] [Abstract][Full Text] [Related]
20. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
